Active surveillance (AS) for ductal carcinoma in situ (DCIS) is emerging as a promising alternative to immediate surgery. A randomized trial suggests that women with DCIS who opted for AS had comparable invasive breast cancer-free (iiBCS) survival on the side of the affected breast. The study compared an active surveillance group with a group that underwent immediate surgery. The results suggest that AS could be a suitable option for some patients with DCIS. Although AS is promising, the article suggests that it is not yet a fully standard treatment option for DCIS. Further studies are needed to confirm long-term results and identify patients who would benefit most from AS.